Drug intelligence / Profile preview

RD07

Development stage: Preclinical
Lead developer: NucMito Pharmaceuticals
Modality: Small Molecules

Overview

RD07 is a preclinical-stage small molecule being developed by NucMito Pharmaceuticals for the treatment of pulmonary fibrosis. The drug is part of a pipeline originating from NucMito's research into nuclear receptor-mediated mitochondrial regulation. While specific details regarding its molecular target have not been disclosed, the candidate is designed to address the underlying pathology of fibrotic lung disease. As of early 2024, RD07 remains in the preclinical phase of development.

Targets

RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on RD07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD07.

Explore the full profile